Brokers Offer Predictions for Mednax, Inc’s Q3 2017 Earnings (MD)
Mednax, Inc (NYSE:MD) – Stock analysts at KeyCorp cut their Q3 2017 earnings estimates for shares of Mednax in a research note issued to investors on Sunday. KeyCorp analyst J. Gurda now anticipates that the company will post earnings of $0.77 per share for the quarter, down from their previous estimate of $0.80. KeyCorp has a “Overweight” rating and a $51.00 price objective on the stock. KeyCorp also issued estimates for Mednax’s Q4 2017 earnings at $0.79 EPS and FY2017 earnings at $3.06 EPS.
Mednax (NYSE:MD) last issued its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843.00 million for the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the prior year, the firm posted $1.03 earnings per share. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/19/brokers-offer-predictions-for-mednax-incs-q3-2017-earnings-md.html.
MD has been the topic of several other research reports. BidaskClub downgraded Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Robert W. Baird reaffirmed a “hold” rating and set a $47.00 target price on shares of Mednax in a report on Sunday, September 3rd. Jefferies Group LLC set a $46.00 target price on Mednax and gave the stock a “hold” rating in a report on Sunday, July 30th. Mizuho reaffirmed a “neutral” rating and set a $48.00 target price (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Finally, ValuEngine downgraded Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company’s stock. Mednax currently has an average rating of “Hold” and an average target price of $58.89.
Mednax (NYSE MD) opened at 43.10 on Tuesday. Mednax has a 52 week low of $41.20 and a 52 week high of $72.13. The stock’s 50 day moving average price is $43.38 and its 200 day moving average price is $56.60. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of 13.73 and a beta of 0.40.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of MD. Eagle Boston Investment Management Inc. grew its holdings in shares of Mednax by 12.9% in the second quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock valued at $11,569,000 after acquiring an additional 21,895 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Mednax by 55.2% in the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after acquiring an additional 28,301 shares in the last quarter. Mn Services Vermogensbeheer B.V. grew its holdings in shares of Mednax by 527.2% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock valued at $919,000 after acquiring an additional 12,800 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Mednax by 7.9% in the first quarter. Prudential Financial Inc. now owns 58,520 shares of the company’s stock valued at $4,060,000 after acquiring an additional 4,270 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Mednax by 3.0% in the second quarter. Swiss National Bank now owns 341,700 shares of the company’s stock valued at $20,628,000 after acquiring an additional 9,900 shares in the last quarter.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.